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Abstract: Rat exposure to 60% O2 (hyper-60) or 85% O2 (hyper-85) for 7
days confers susceptibility or tolerance, respectively, of the otherwise lethal
effects of exposure to 100% O2. The objective of this study was to determine
whether activities of the antioxidant cytosolic enzyme NAD(P)H:quinone
oxidoreductase 1 (NQO1) and mitochondrial complex III are differentially
altered in hyper-60 and hyper-85 lungs. Duroquinone (DQ), an NQO1
substrate, or its hydroquinone (DQH2), a complex III substrate, was infused
into the arterial inflow of isolated, perfused lungs, and the venous efflux rates
of DQH2 and DQ were measured. Based on inhibitor effects and kinetic
modeling, capacities of NQO1-mediated DQ reduction (Vmax1) and complex IIImediated DQH2 oxidation (Vmax2) increased by ∼140 and ∼180% in hyper-85
lungs, respectively, compared with rates in lungs of rats exposed to room air
(normoxic). In hyper-60 lungs, Vmax1 increased by ∼80%, with no effect on
Vmax2. Additional studies revealed that mitochondrial complex I activity in
hyper-60 and hyper-85 lung tissue homogenates was ∼50% lower than in
normoxic lung homogenates, whereas mitochondrial complex IV activity was
∼90% higher in only hyper-85 lung tissue homogenates. Thus NQO1 activity
increased in both hyper-60 and hyper-85 lungs, whereas complex III activity
increased in hyper-85 lungs only. This increase, along with the increase in
complex IV activity, may counter the effects the depression in complex I
activity might have on tissue mitochondrial function and/or reactive oxygen
species production and may be important to the tolerance of 100% O 2
observed in hyper-85 rats.
Keywords: oxidative stress, mathematical modeling, duroquinone,
cytochrome bc1 complex, cytochrome-c oxidase

High o2 therapy (hyperoxia) is a necessary and effective initial
treatment of hypoxemia or low blood Po2 in adult and pediatric
patients with acute lung injury, such as acute respiratory distress
syndrome.50,57 While improving O2 delivery to vital organs, sustained
exposure to O2 at high fractions (>50%) impairs lung function.27,38,47
Presently, the underlying mechanisms of lung O2 toxicity are not fully
understood, and new strategies to reduce the toxic effects of this
widely used therapy are needed.4,21
Several animal models have been developed to evaluate the
time course, severity, and pathophysiological mechanisms of lung O2
toxicity.24,30,54,69 The rat model is unique in that, when adult rats are
exposed to a sublethal 85% O2 (hyper-85) environment for 5–7 days,
they acquire tolerance to the otherwise lethal effects of 100% O2, in
that, if transferred to a 100% O2 environment, they survive for
prolonged periods.6,24,33 This tolerance is not observed in other rodent
species, but a similar tolerance occurs in humans.19,24,26,32 Conversely,
rats exposed to 60% O2 (hyper-60) for 7 days become more
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susceptible to 100% O2.23,40 Elucidating the factors that contribute to
this tolerance or susceptibility of rats to 100% O2 will further
understanding of the pathogenesis of lung O2 toxicity. In turn, this
may suggest strategies for clinicians at the bedside to protect lung
tissue from the toxic effects of sustained exposure to high O2.6,24,26,33
There is ample evidence that the deleterious effects of high O2
result from increased formation of reactive oxygen species
(ROS).22,31,34,46 Thus previous studies have suggested a role for classic
antioxidant enzymes (e.g., superoxide dismutases) in protection from
O2 toxicity.24,26,42,43 Although the activities of some of these enzymes
increase in lung homogenates from rats adapted to lethal hyperoxia,
they do not appear to account for all aspects of this adaptive
response.18,23,41,69
Another proposed mechanism involved in rat tolerance of 100%
O2 is the induction of phase II detoxification enzymes, including
NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione-Stransferase, and heme oxygenase-1.20,48 The induction occurs via the
antioxidant response element, in response to oxidative or electrophilic
stress.20,48 Phase II enzymes are, in general, involved in detoxification
of reactive electrophilic metabolites via two-electron reduction.16,20,29
With respect to NQO1, which is predominantly a cytosolic two-electron
reductase,13,55 additional protective effects include regeneration of
endogenous and exogenous antioxidants,12,29,60 scavenging
superoxide,59,71 and competition with prooxidant one-electron quinone
reductases (e.g., P-450 reductases) for reactive electrophilic
metabolites and other redox active compounds.16,51,55,56,70
Mitochondrial complexes I and III are a major source of ROS,
and their rate of ROS production increases with O2 tension.15,66 Thus
altering the activity of mitochondrial complex I and/or complex III
would be an approach to control the rate of ROS production in
response to increased O2 tension and to protect lung tissue.18
To evaluate the activities of redox metabolic processes in a
nondestructive manner in isolated perfused lungs, we have pursued
the use of indicator dilution methods.5–7,9,10 These methods involve the
bolus injection or finite-pulse infusion of indicators into the lung's
arterial inlet, followed by measurement of concentrations of these
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indicators in the venous effluent as a function of time. The injected
indicators usually include an intravascular indicator plus a test
indicator that is a substrate or ligand for the organ's metabolic
function(s) of interest. The interactions of the test indicator with
metabolic function(s) on passage though the organ result in
characteristic differences between the intravascular and test indicator
venous effluent concentration vs. time curves. The information in
these curves about these metabolic function(s) is then deciphered
using mathematical modeling5,9,10
Using these indicator dilution methods and mathematical
modeling, we have demonstrated that the redox active quinone
compound duroquinone (DQ) is reduced to durohydroquinone (DQH2),
and DQH2 is oxidized to DQ on passage through the pulmonary
circulation of the isolated perfused rat lung.5,6 Based on inhibitor
studies, NQO1 was implicated as the dominant DQ reductase and
mitochondrial complex III as the dominant DQH2 oxidase, and the
capacities of the lung to reduce DQ to DQH2 and oxidize DQH2 to DQ
were shown to be measures of lung NQO1 activity and complex III
activity, respectively.5,6
The objective of the present study was to evaluate the effects of
a 7-day exposure of rats to hyper-60 or hyper-85 on activities of
NQO1 and complex III in the intact lung using DQ and DQH2,
respectively, as indicator dilution probes. Demonstration that the
activity of a particular redox enzyme is differentially altered by
exposure to hyper-60 and hyper-85 would suggest a role in the
development of the observed rat tolerance of, or susceptibility to,
100% O2 toxicity.

Methods
Materials.
DQ and other reagent grade chemicals were purchased from
Sigma Chemical (St. Louis, MO). Bovine serum albumin (BSA;
Standard Powder) was purchased from Serologicals (Gaithersburg,
MD). DQH2 was prepared by reduction of DQ with potassium
borohydride, as previously described.17
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Animals.
For normoxic lung studies, male Sprague-Dawley rats (275–325
g; Charles River) were exposed to room air. For the hyperoxic lung
studies, age-matched rats were housed in a Plexiglas chamber
maintained at approximately hyper-60 or hyper-85, balance N2, for 7
days with free access to food and water.6 The total gas flow was 3.5
l/min, and the chamber CO2 was maintained at <0.5%. The
temperature within the chamber was maintained at 20–22°C. Every
other day, the rats were weighed, and their cage, food, water, and CO2
absorbent were changed. The protocol was approved by the
Institutional Animal Care and Use Committees of the Zablocki Veterans
Affairs Medical Center and Marquette University (Milwaukee, WI).

Isolated, perfused lung experiments.
As previously described, rats were anesthetized with
pentobarbital sodium (40 mg/kg body wt ip), the trachea was
clamped, the chest opened, and heparin (0.7 IU/g body wt) injected
into the right ventricle. The pulmonary artery and the trachea were
cannulated, and the pulmonary venous outflow was accessed via a
cannula in the left atrium. The lung was removed from the chest and
attached to a ventilation and perfusion system. The control perfusate
contained (in mM) 4.7 KCl, 2.51 CaCl2, 1.19 MgSO4, 2.5 KH2PO4, 118
NaCl, 25 NaHCO3, 5.5 glucose, and 5% BSA.5 The single-pass
perfusion system was primed (Masterflex roller pump) with the control
perfusate maintained at 37°C and equilibrated with 15% O2, 6% CO2,
balance N2, resulting in perfusate Po2, Pco2, and pH of ∼105 Torr, 40
Torr, and 7.4, respectively. Initially, control perfusate was pumped
through the lung until it was evenly blanched and venous effluent was
clear of blood. The lung was ventilated (40 breaths/min) with endinspiratory and end-expiratory pressures of ∼6 and 3 mmHg,
respectively, with the above gas mixture. The pulmonary arterial
pressure was referenced to atmospheric pressure at the level of the
left atrium and monitored continuously during the course of the
experiments. The venous effluent pressure was atmospheric pressure.
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Pulse infusion experimental protocols.
To determine the DQ reducing capacity of the lung, four 135-s
sequential arterial pulse infusions at DQ concentrations of 50, 100,
200, and 400 μM were carried out with a perfusate flow of 10 ml/min.
For each pulse infusion, a venous effluent sample (1 ml) was collected
between 130 and 135 s after initiation of the pulse infusion. Infusion
for 130 s is long enough for the venous effluent concentrations of DQ
and DQH2 to reach steady state.5,6 Between pulse infusions, the lung
was perfused with 30 ml of fresh perfusate to wash the lung and
perfusion system of any remaining traces of DQ and/or DQH2. For
some of the lungs, the 400 μM DQ pulse infusion was repeated after
lung treatment with the NQO1 inhibitor dicumarol (400 μM).
To determine the capacity of NQO1-mediated DQ reduction on
passage through the pulmonary circulation, each lung was perfused for
5 min with perfusate containing antimycin A (10 μM) to inhibit complex
III mediated DQH2 oxidation.14 This was followed by four successive
DQ pulse infusions, as above, with the inhibitor present throughout the
infusion protocol.
To evaluate the capacity of complex III-mediated DQH2
oxidation on passage through the pulmonary circulation, each lung
was perfused for 5 min with perfusate containing dicumarol (NQO1
inhibitor; 400 μM) or dicumarol plus rotenone (complex I inhibitor; 20
μM).5,6,9 This was followed by four 135-s sequential arterial pulse
infusions at DQH2 concentrations of 50, 100, 200, and 400 μM at a
flow of 10 ml/min, with the inhibitors present throughout the infusion
protocol. A 1-ml venous effluent sample was collected between 130
and 135 s after initiation of each pulse infusion. For some of the lungs,
the 400 μM DQH2 infusion was repeated after lung perfusion with
antimycin A.
For determination of perfused lung surface area, a 150 μM 20-s
pulse infusion of the angiotensin converting enzyme (ACE) substrate
N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly (FAPGG) was carried out at a
perfusate flow of 30 ml/min.6 Two 1-ml venous effluent samples were
collected between 15 and 20 s after the start of the FAPGG infusion.6
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Determination of DQ and DQH2 concentrations in
venous effluent samples.
The concentrations of DQ and DQH2 in the venous effluent
samples were determined as previously described.5 At steady state, 92
± 3% (SD) and 95 ± 4% (SD) of the infused DQ and DQH2,
respectively, were recovered in the total venous effluent as DQ +
DQH2, with the loss attributable primarily to binding of both forms to
the experimental tubing (data not shown).

Steady-state DQH2 or DQ efflux rates.
The steady-state efflux rates of DQH2 or DQ from the lung
during DQ or DQH2 arterial infusion were calculated as the product of
the perfusate flow (10 ml/min) and the steady-state venous effluent
DQH2 or DQ concentrations, respectively.

Log mean DQ and DQH2 concentrations.
DQ vascular concentration during DQ arterial infusion decreases
as it passes through the capillary region due to reduction. Thus the
effective DQ concentration in the capillary region during DQ arterial
infusion is given by its log mean,

Log mean DQ conc. =

̅̅̅̅]in − [DQ
̅̅̅̅]out
[DQ
̅̅̅̅]in /[DQ
̅̅̅̅]out )
ln([DQ
(1)

̅̅̅̅]in and [DQ
̅̅̅̅]out are the arterial infused and venous effluent
where [DQ
steady-state DQ concentrations, respectively5 Similarly, the effective
DQH2 concentration in the capillary region during DQH2 arterial
infusion is given by,

Log mean DQH2 conc. =

̅̅̅̅̅̅2 ]in − [DQH
̅̅̅̅̅̅2 ]out
[DQH
̅̅̅̅̅̅2 ]in /[DQH
̅̅̅̅̅̅2 ]out )
ln([DQH
(2)
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̅̅̅̅̅̅2 ]in and [DQH
̅̅̅̅̅̅2 ]out are the arterial infused and venous
where [DQH
effluent steady-state DQH2 concentrations, respectively.
Determination of perfused capillary surface area.
The linear steady-state rate of ACE-mediated FAPGG hydrolysis is
represented as a permeability-surface area product (PS, ml/min)
defined by Eq. 3 :6

PS=−F ln(1−E)
(3)
where E = steady-state extraction ratio = 1 − [FAPGG]o/[FAPGG]i;
[FAPGG]i is the infused arterial FAPGG concentration; [FAPGG]o is the
steady-state venous effluent FAPGG concentration calculated as the
average [FAPGG] in the collected venous effluent samples; and F is the
perfusate flow.6 In the present study, the PS product is considered to
be an index of perfused capillary endothelial surface area.5,6,9

Lung homogenate NQO1 activity.
For this assay, the lungs were perfused with perfusate
containing 2.5% Ficoll instead of 5% BSA, weighed, and placed in icecold buffer (5 ml/g lung tissue, pH 7.4) containing (in mM) 10 N-2hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 250
sucrose, 3 EDTA, 1 phenylmethylsulfonyl fluoride, and 1% protease
inhibitor cocktail (Sigma catalog no. P8340). The lungs were first
minced and then homogenized at 4°C using a Polytron tissue
homogenizer (Kinematica, Luzern, Switzerland). The lung homogenate
was centrifuged (12,100 g) at 4°C for 30 min, and the supernatant
was collected and kept at 4°C. The supernatant protein concentration
and NQO1 activity were measured as previously described.6

Complexes I and IV assays.
The lungs were perfused with perfusate containing 2.5% Ficoll
instead of 5% BSA, weighed, minced, and homogenized as above with
buffer (pH 7.2) containing (in mM) 225 mannitol, 75 sucrose, 5 3-(Nmorpholino)propanesulfonic acid, 20 ethylene glycol-bis(β-aminoethyl
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ether)-N,N,N′,N′-tetraacetic acid, 2% fatty-acid free BSA, and 0.02
ml/ml protease inhibitor cocktail set III (Calbiochem, La Jolla, CA),
utilizing a Polytron tissue homogenizer. Lung homogenates were
centrifuged at 1,500 g for 5 min at 4°C, and the resulting supernatants
were centrifuged again at 13,000 g for 30 min at 4°C to obtain a crude
mitochondrial fraction (P2). The P2 fractions were washed twice by
resuspension in 8 ml ice-cold homogenization buffer without BSA and
then centrifuged (13,000 g for 20 min at 4°C). The final P2 fractions
were resuspended in 1-ml BSA-free homogenization buffer. Complex I
activity was measured using the method of Lenaz et al.,44 as
previously described.9 Mitochondrial complex IV activity was measured
as described by Storrie and Madden61 using ferrocytochrome c as the
substrate. The protein concentrations were determined as previously
described.6,9

Total glutathione content.
For this assay, the lungs were perfused with buffer containing
(in mM) 10 HEPES, 5 glucose, and 5% dextran (∼67,000 mol wt), pH
7.4. The lungs were then dissected free from connective tissue and
weighed. The tissue was then placed into 10 volumes (per lung wet
weight) of 4°C sulfosalicylic acid (5%), minced, and homogenized as
above. The homogenate was centrifuged (10,000 g) at 4°C for 20 min,
and the supernatant was used to determine total lung glutathione
content, as described by Owens and Belcher49 and modified by Tietze65
and Griffith.39

Statistical evaluation of data.
Statistical comparisons were carried out using t-test or ANOVA
followed by Tukey's test, with P < 0.05 as the criterion for statistical
significance.

Results
Rats lost ∼14% of their preexposure body weights (Fig. 1) over
the 7-day hyper-85 exposure period, consistent with results from
previous studies.24,52 Most of this weight loss occurred between days 2
and 6, during which the rats' water and food intake decreased
substantially. On the other hand, rats exposed to hyper-60 gained
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body weight steadily over the 7-day exposure period at a rate that is
virtually the same as that of age-matched normoxic rats.23 Subsequent
determination of model parameters is unaffected by the body weight
loss of hyper-85 rats, since normalization is done with respect to dry
lung weight rather than body weight.

Fig. 1. Rat body weights normalized to preexposure body weights at different time
points during the 7-day exposure period to room air (normoxic), 60% O2 (hyper-60),
or 85% O2 (hyper-85). Values are means ± SE (n = 6, 33, and 34 for normoxic,
hyper-60, and hyper-85 rats, respectively). Normalized weights at a given time are
significantly different from normalized weights at the previous time point for
*normoxic, # hyper-60, or & hyper-85 rats, respectively (P < 0.05).

Rat exposure to hyper-85 for 7 days (hyper-85) increased lung
wet weight by 87%, with no significant effect on wet-to-dry weight
ratio compared with normoxic lungs (Table 1). The lack of a significant
difference in wet-to-dry weight ratios between normoxic and hyper-85
lungs (Table 1) is consistent with the finding of Crapo et al.24 that the
increase in wet weight was due to increased tissue mass not edema.
Hyper-60 lung wet weights and wet-to-dry weight ratios were not
different from normoxic lungs (Table 1).40
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Table 1. Rat body weights, lung weights, lung wet-to-dry weight ratio, ACE
activity, and aortic blood Hct
Body Weight, g

Wet Weight, g Wet-to-Dry Ratio PS, ml/min

Hct, %

Normoxic

316 ± 4

1.22 ± 0.03

5.56 ± 0.09

24.7 ± 1.7

43.5 ± 0.4

Hyper-60

302 ± 2*

1.31 ± 0.02

5.45 ± 0.05

25.1 ± 1.4

33.5 ± 0.6*

Hyper-85

311 ± 2

2.29 ± 0.08

*†

5.72 ± 0.08

10.7 ± 0.8

*†

50.1 ± 0.8*†

Values are means ± SE; n values are as follows for body weight, lung wet weight, wetto-dry ratio, permeability surface area product (PS), and hematocrit (Hct),
respectively: normoxic lungs, n = 38, 38, 31, 19, and 27 (38 is the total number of
normoxic rats studied); hyper-60 (60% O2 exposure) lungs, n = 38, 38, 29, 18, and
23 (38 is the total number of hyper-60 rats studied); hyper-85 (85% O2 exposure)
lungs, n = 41, 41, 28, 20, and 27 (41 is the total number of hyper-85 rats studied).
Body weight is the value at the beginning of the 7-day exposure period. PS is measure
of angiotensin-converting enzyme (ACE) mediated N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly
hydrolysis and an index of perfused capillary surface area. Significantly different from
* normoxic and †hyper-60 values, P < 0.05.

Exposure to hyper-85 for 7 days decreased PS (ml/min), an
index of perfused capillary endothelial surface area, by 56% compared
with normoxic lungs (Table 1). This is consistent with the 50%
decrease in capillary volume and endothelial surface area measured
morphometrically.24,25,52 The PS values for hyper-60 and normoxic
lungs were not significantly different. This is consistent with no change
in morphometric measures of capillary volume and endothelial surface
area between normoxic and hyper-60 lungs.40
Rat exposure to hyper-85 and hyper-60 had a differential effect
on aortic blood hematocrit (Table 1). Exposure to hyper-85 increased
hematocrit by 16%, while exposure to hyper-60 decreased it by 12%
compared with normoxic lungs.24 The increase in aortic blood
hematocrit of hyper-85 rats is consistent with that reported in previous
studies.24,25 Those studies suggested that this decrease could be due
to dehydration, consistent with the measured body weight loss in
hyper-85 rats (Table 1). There was no significant difference in the
isolated lung perfusion pressure at 10 ml/min among the three groups
of lungs.52
For hyper-60 and hyper-85 lungs, the DQH2 efflux rates during
the arterial infusion of DQ at the two highest concentrations were, on
average, 37% higher than in normoxic lungs (Fig. 2). For all three lung
groups, lung treatment with dicumarol (NQO1 inhibitor) decreased the
rate of DQH2 efflux by >95% during the infusion of DQ at the highest
concentration. This is consistent with NQO1 being the dominant
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reductase of DQ on passage through the pulmonary circulation of
normoxic, hyper-60, and hyper-85 lungs.5,6

Fig. 2. The relationship between the steady-state rate of durohydroquinone (DQH2)
efflux and the log mean duroquinone (DQ) concentrations, which are effective
intravascular DQ concentrations during DQ arterial infusion, for normoxic lungs (n =
4), hyper-85 lungs (n = 5), and hyper-60 lungs (n = 5). Values are means ± SE. The
solid lines are model fits to the mean values of the data. *Hyper-60 rates significantly
different from the normoxic rates at the same log mean DQ concentrations; # hyper85 rates significantly different from the normoxic rates at the same log mean DQ
concentrations (P < 0.05).

To evaluate the capacity of the lung to oxidize DQH2, we
measured the steady-state rate of DQ efflux during DQH2 infusion in
the presence of dicumarol to inhibit DQ reduction (Fig. 3). For hyper60 and hyper-85 lungs, the rates of DQ efflux during DQH2 infusion at
the two highest concentrations were 40% higher than in normoxic
lungs (Fig. 3). For all three groups of lungs, treatment with antimycin
A (complex III inhibitor) decreased the rate of DQ efflux to nearly zero
during DQH2 infusion at the highest concentration. This is consistent
with DQH2 oxidation on passage through normoxic and hyperoxic lungs
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occurring predominately via the hydroquinone oxidase-cytochrome c
reductase activity of complex III.5,6

Fig. 3. The relationship between the steady-state rate of DQ efflux and the log mean
DQH2 concentrations, which are the effective intravascular DQH2 concentrations during
DQH2 arterial infusion in the presence of dicumarol (DIC, 400 μM), for normoxic lungs
(n = 6), hyper-85 lungs (n = 6), and hyper-60 lungs (n = 4). Values are means ± SE.
The solid lines are model fits to the mean values of the data. *Hyper-60 rates
significantly different from the normoxic rates at the same log mean DQH2
concentrations; # hyper-85 rates significantly different from the normoxic rates at the
log mean DQH2 concentrations (P < 0.05).

To evaluate the effect of rat exposure to hyper-60 or hyper-85
on NQO1-mediated DQ reduction, the rate of DQH2 efflux during DQ
infusion was measured in the presence of antimycin A to inhibit DQH2
oxidation (Fig. 4). As expected, antimycin A increased the rates of
DQH2 efflux (Figs. 2 and and 4) over the range of infused DQ
concentrations. Moreover, both O2 levels increased the rate of DQH2
efflux during DQ infusion at the two highest concentrations in the
presence of antimycin A compared with normoxic lungs, but the
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increase was larger for the hyper-85 lungs (52%) than for the hyper60 lungs (23%) (Fig. 4).

Fig. 4. The relationship between the steady-state rate of DQH2 efflux and the log
mean DQ concentrations, which are the effective intravascular DQ concentrations
during DQ arterial infusion in the presence of antimycin A (AA, 10 μM), for normoxic
lungs (n = 5), hyper-85 lungs (n = 5), and hyper-60 lungs (n = 5). Values are means
± SE. The solid lines are model fits to the mean values of the data. *Hyper-60 rates
significantly different from the normoxic rates at the same log mean DQ
concentrations; # hyper-85 rates significantly different from the normoxic rates at the
same log mean DQ concentrations (P < 0.05).

To evaluate the effect of rat exposure to hyper-85 or hyper-60
on mitochondrial complex III-mediated DQH2 oxidation, the rate of DQ
efflux during DQH2 infusion was measured in the presence of
dicumarol and rotenone. Again, rotenone was added to minimize
competition between DQH2 and reduced endogenous coenzyme Q9
hydroquinone (CoQ9H2) for oxidation via complex III. Figure 5 shows
that, for hyper-85 lungs, the steady-state rates of DQ efflux during
DQH2 infusion at the two highest concentrations in the presence of
dicumarol plus rotenone were ∼30% higher than those in normoxic
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lungs. For all three groups of lungs, the rate of DQ efflux during DQH2
infusion at the highest concentration in the presence of antimycin A
along with dicumarol and rotenone was virtually zero. This further
supports that complex III is the dominant site for DQH2 oxidation on
passage through the pulmonary circulation of all three groups of lungs.

Fig. 5. The relationship between the steady-state rate of DQ efflux and the log mean
DQH2 concentrations, which are the effective intravascular DQH2 concentrations during
DQH2 arterial infusion in the presence of DIC (400 μM) plus rotenone (ROT, 20 μM),
for normoxic lungs (n = 4), hyper-85 lungs (n = 4), and hyper-60 lungs (n = 4).
Values are means ± SE. The solid lines are model fits to the mean values of the data.
& Hyper-85 rates significantly different from the normoxic rates at the same log mean
DQH2 concentrations (P < 0.05).

Table 2 shows that rat exposure to hyper-85 increased NOQ1
homogenate activity per lung by 72%, but had no significant effect on
NQO1 activity per milligram of protein. Exposure to hyper-60, on the
other hand, had no significant effect on NQO1 activity in homogenate
per lung or per milligram of protein.
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Table 2. Lung homogenate NQO1 activity
Homogenate NQO1 Activity
μmol · min−1 · lung−1

nmol · min−1 · mg protein−1

Normoxic

26.48 ± 1.67

670 ± 80

Hyper-60

34.75 ± 1.98

737 ± 63

Hyper-85
45.55 ± 4.74*†
538 ± 43
Values are means ± SE; n = 7, 10, and 7 for normoxic, hyper-60, and hyper-85 lungs,
respectively. NQO1, NAD(P)H:quinone oxidoreductase 1. Significantly different from
the corresponding * normoxic and † hyper-60 values, P < 0.05.

We also measured the activities of mitochondrial complexes I
and IV in lung tissue homogenates. Table 3 shows that mitochondrial
complex I activities per milligram protein were ∼50% lower in P2
fractions derived from hyper-85 and hyper-60 lungs than normoxic
lungs. Complex IV activity per milligram protein increased in only
hyper-85 lung homogenates by 90% compared with normoxic lungs
(Table 3).
Table 3. Mitochondrial complexes I and IV activities measured in P2 fractions
of lung homogenates
Complex I Activity

Complex IV Activity

Normoxic

13.18 ± 2.31

231.8 ± 15.9

Hyper-60

6.49 ± 0.84*

201.8 ± 45.8

1.24*

Hyper-85
6.78 ±
439.3 ± 50.8*
−1
−1
Values are means ± SE in nmol · min · mg protein ; for complexes I and IV
activities, n = 5, 5, and 7 for normoxic, hyper-60, and hyper-85 lungs, respectively.
*Significantly different from the corresponding normoxic value, P < 0.05.

Table 4 shows that total glutathione content (oxidized plus
reduced glutathione) per lung and per gram of dry lung weight
increased by 101 and 20%, respectively, in hyper-85 lungs only
compared with normoxic lungs.
Table 4. Total lung glutathione (GSH + GSSG) content
(GSH + GSSG), μmol/lung

(GSH + GSSG), μmol/g dry wt

Normoxic

2.34 ± 0.17

10.23 ± 0.55

Hyper-60

3.09 ± 0.14

11.96 ± 0.77

0.39*†

Hyper-85
4.70 ±
12.21 ± 0.47*
Values are means ± SE; n = 8, 5, and 7 for normoxic, hyper-60, and hyper-85 lungs,
respectively. GSH, reduced glutathione; GSSG oxidized glutathione. Significantly
different from the corresponding * normoxic and † hyper-60 values, P < 0.05.
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Data analysis.
The data in Figs. 22–5 are the net result of multiple factors,
including 1) DQ and DQH2 interactions with competing nonlinear tissue
redox processes; 2) DQ and DQH2 interactions with protein (i.e., BSA)
in the vascular space; and 3) capillary perfusion kinematics [i.e., a
heterogeneous distribution, hc(t), of capillary transit times]. Thus, for
quantitative interpretation of the data in Figs. 22–5, we utilized a
whole lung kinetic model consisting of a capillary region that accounts
for DQ and DQH2 tissue and vascular interactions and conducting
arteries and veins.52 The capillary region has a hc(t).5,6,9 The model
was used to estimate parameters descriptive of the activities of NQO1
and complex III in the isolated perfused lung from the data in Figs. 22
–5.
The capillary region is modeled as parallel noninteracting
capillary elements with transit times distributed according to hc(t).8
Figure 6 shows a single capillary element consisting of a vascular
region and its surrounding lung tissue region with volumes Vc (ml) and
Ve (ml), respectively. Within the vascular region, DQ and DQH2
participate in nonspecific and rapidly equilibrating interactions with the
perfusate albumin (BSA). The free (i.e., not BSA bound) vascular
concentrations of DQ and DQH2 can freely permeate the tissue region
from the vascular region. Within the tissue region, DQ is reduced via
NQO1, and DQH2 is oxidized via mitochondrial complex III. This
reduction and oxidation are assumed to follow Michaelis-Menten
kinetics, where Vmax and Km represent the maximum reduction or
oxidation rate and Michaelis-Menten constant, respectively. All
nonspecific DQ and DQH2 interactions are assumed to follow the law of
mass action. The above assumptions were incorporated into a
differential equation model presented in the appendix.
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Fig. 6. A schematic representation of the vascular and lung tissue interactions of DQ
and DQH2 in a single capillary element consisting of a vascular region and its
surrounding tissue region. Within the vascular region, DQ and DQH2 participate in
nonspecific and rapidly equilibrating interactions with the perfusate BSA, Pc. Within the
tissue region, DQ is reduced via NAD(P)H:quinone oxidoreductase 1 (NQO1), and
DQH2 is oxidized via complex III. Also within the tissue volume, DQ and DQH2 undergo
nonspecific rapidly equilibrating interactions with lung tissue, Pe. CytoC (oxid.) and
cytoC (red.) are the oxidized and reduced forms of cytochrome c, respectively.

Estimation of model parameters.
The unknown model parameters under steady-state conditions
(see appendix) are Vmax1 (μmol/min) and Vmax2 (μmol/min), the
respective maximum rates for DQ reduction via NQO1 and DQH2
oxidation via complex III; Km1a (μM) and Km2a (μM), the apparent
Michaelis-Menten constants for NQO1-mediated DQ reduction and
complex III-mediated DQH2 oxidation, respectively; and kox (ml/min),
the tissue-mediated DQH2 oxidation rate on passage through the
pulmonary circulation in the absence of rotenone.
The values of these parameters for each of the three groups of
lungs were estimated using the following approach. First, the values of
Vmax1 and Km1a, parameters descriptive of NQO1-mediated DQ
reduction, were determined. This was done by fitting the steady-state
solution of the lung model to the steady-state rates of DQH2 efflux
during DQ infusion in the presence of antimycin A (Fig. 4), which
corresponded to setting Vmax2 to zero in Eqs. A1 and A2. The estimated
values of these model parameters are given in Table 5. Rat exposure
to hyper-85 for 7 days increased Vmax1 by ∼200%. The estimated
values of Vmax1 for hyper-60 lungs tended to be higher than those for
normoxic lungs, but the mean difference was not significant (one-way
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ANOVA). For all three groups of lungs, the estimated value of Km1a was
1 μM, which was the lower bound set for this parameter in the least
squares fitting procedure. Km1a is an intensive property of the enzyme
and hence would be expected to be the same for all three groups of
lungs.
Table 5. Values of model parameters descriptive of NQO1-mediated DQ
reduction in normoxic and hyperoxic lungs estimated from the steady-state
DQH2 efflux rates during DQ infusion in the presence of antimycin A
Vmax1
μmol/min

μmol · min−1 · g dry wt−1

Kma1, μM

Normoxic

1.38 ± 0.07

6.4 ± 0.3

1.0

Hyper-60

1.84 ± 0.06

7.8 ± 0.5

1.0

Hyper-85
4.11 ± 0.39*†
10.8 ± 0.7*†
1.0
Values are means ± SE; n = 5 for all three groups. Vmax1, maximum duroquinone (DQ)
reduction rate; Kma1, apparent Michaelis-Menten constant. DQH2, durohydroquinone.
Significantly different from * normoxic and † hyper-60 values, P < 0.05.

For a given lung, parameters descriptive of complex IIImediated DQH2 oxidation (Vmax2 and Km2a) were estimated by fitting
the steady-state solution of the organ model to the rates of DQ efflux
during DQH2 infusion in the presence of dicumarol and rotenone (Fig.
5), with Vmax1 set to zero in Eqs. A1 and A2 to account for the presence
of dicumarol. Results in Table 6 show that exposure to hyper-85
increased Vmax2 by ∼180%, compared with normoxic lungs, with no
significant effect on Km2a. The estimated values of Vmax2 and Km2a for
hyper-60 lungs were not significantly different from those estimated
for normoxic lungs.
Table 6. Values of model parameters descriptive of complex III-mediated
DQH2 oxidation in normoxic and hyperoxic lungs estimated from the steadystate DQ efflux rates during DQH2 infusion in the presence of dicumarol plus
rotenone
Vmax2
μmol/min

μmol · min−1 · g dry wt−1

Kma2, μM

Normoxic

1.67 ± 0.10

8.7 ± 0.7

42 ± 2

Hyper-60

2.07 ± 0.09

8.8 ± 0.5

38 ± 6

0.36*†

1.8*†

Hyper-85
4.65 ±
13.6 ±
36 ± 11
Values are means ± SE. n = 4 for all three groups. Vmax2, maximum DQH2 oxidation
rate; Kma2, apparent Michaelis-Menten constant. Significantly different from *
normoxic and † hyper-60 values, P < 0.05.
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In the absence of rotenone (complex I inhibitor), DQH2
competes with CoQ9H2 for oxidation via complex III. This competition
explains the observation that the rates of DQ efflux during DQH2
infusion in the presence of dicumarol alone are lower than those in the
presence of dicumarol plus rotenone (Figs. 3 and and 5). Moreover,
the steady-state DQ efflux rates during DQH2 infusion in the presence
of dicumarol alone appear to follow linear kinetics for the range of
infused DQH2 concentrations studied (Fig. 3). Thus, in the absence of
rotenone, Vmax2 and Km2a in Eqs. A1 and A2 (appendix) are substituted
for with kox (Eqs. A3 and A4). To put kox in perspective, if one were to
assume Michaelis-Menten kinetics for DQH2 oxidation in the presence
of dicumarol alone, kox would be the ratio of the maximum oxidation
rate over the Michaelis-Menten constant.
The value of kox was estimated by fitting the model, with Vmax1
set to zero in Eqs. A3 and A4, to the steady-state rates of DQH2 efflux
during DQ infusion in the presence of dicumarol (Fig. 3). Table 7
shows that rat exposure to hyper-60 or hyper-85 for 7 days increased
the estimated value of kox by ∼70 and ∼140%, respectively, compared
with normoxic lungs.
Table 7. Value of model parameter descriptive of the DQH 2 oxidation capacity
in normoxic and hyperoxic lungs estimated from the steady-state DQ efflux
rates during DQH2 infusion in the presence of dicumarol
kox
ml/min

ml · min−1 · g dry wt−1

Normoxic

6.38 ± 0.60

27.6 ± 2.9

Hyper-60

10.84 ± 1.25*

43.1 ± 4.0*‡

Hyper-85
15.16 ± 1.58*†
35.0 ± 8.4
Values are means ± SE; n = 6, 4, and 6 for normoxic, hyper-60, and hyper-85 lungs,
respectively. kox, rate of DQH2 oxidation on passage through the pulmonary
circulation. Significantly different from * normoxic, † hyper-60, and ‡ hyper-85
values, P < 0.05.

A second estimate of the values of Vmax1 and Km1a for normoxic
and hyperoxic lungs was obtained by fitting the steady-state organ
model solution to the steady-state rates of DOH2 efflux during DQ
infusion in the absence of inhibitors (Fig. 2), with kox in Eqs. A3 and A4
set to the mean values in Table 7. The estimated values of Vmax1 for
hyper-60 and hyper-85 lungs were ∼80 and 140% higher than that
estimated for normoxic lungs, respectively (Table 8).
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Table 8. Values of model parameters descriptive of NQO1-mediated DQ
reduction in normoxic and hyperoxic lungs estimated from the steady-state
DQH2 efflux rates during DQ infusion
Vmax1
μmol/min

μmol · min−1 · g dry wt−1

Kma1, μM

Normoxic

1.46 ± 0.10

7.2 ± 0.8

4.4 ± 1.4

Hyper-60

2.64 ± 0.08*

11.8 ± 0.5*

12.5 ± 2.1*‡

Hyper-85

3.52 ± 0.12*†

10.1 ± 0.6*

6.4 ± 1.6

Values are means ± SE; n = 4, 5, and 5 for normoxic, hyper-60, and hyper-85 lungs,
respectively. kox was set to the mean value in Table 5. Significantly different from *
normoxic, † hyper-60, and ‡ hyper-85 values, P < 0.05.

For normoxic and hyper-85 lungs, the values of Vmax1 in Table 8
vs. Table 5, i.e., estimated from the steady-state rates of DQH2 efflux
during DQ infusion in the absence or presence, respectively, of
antimycin A were not significantly different. This is consistent with the
hypothesis that the dominant effect of antimycin A is on complex IIImediated DQH2 oxidation. However, for hyper-60 lungs, the estimated
values of Vmax1 were statistically different for the two approaches.

Discussion
The results of the present study demonstrate that rat exposure
to hyper-85 vs. hyper-60 differentially altered the lung tissue complex
III and IV activities, and GSH content, but had similar effects on NQO1
and complex I activities. In hyper-85 rats, the capacity of Vmax1 and
Vmax2 increased by 140 and 180%, respectively, on passage through
the pulmonary circulation. However, hyper-60 increased Vmax1 by 80%,
with no effect on Vmax2. Additional results demonstrate that hyper-60
and hyper-85 decreased complex I activity by ∼50%, and that hyper85, but not hyper-60, increased complex IV activity and GSH tissue
content by 90 and 20%, respectively.
In addition to increasing Vmax1 and Vmax2, rat exposure to hyper85 increased lung dry weight (Table 1), presumably due to a large
increase in the number of interstitial cells.24,25 This brought into
question whether the estimated increase in these extensive kinetic
parameters was simply the result of an increase in tissue mass (i.e.,
more cells). As shown in Tables 6 and and 8, the increase in the dry
weight of hyper-85 lungs cannot account for all of the increase in the
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values of Vmax1 and Vmax2, since the values per gram of dry lung are,
respectively, 40 and 56% higher than corresponding values for
normoxic lungs. The above results suggest that rat exposure to hyper85 induced an increase of 40 and 56% in the lung activities of NQO1
and complex III per gram of dry lung weight, respectively.
For normoxic and hyper-85 lungs, the estimates of Vmax1
obtained using two independent data sets, i.e., DQH2 efflux rates
during DQ infusion in the absence or presence of antimycin A, are not
significantly different (Tables 5 and and 8). However, for hyper-60
lungs, the difference in these values is 42%. One reason for this
difference might be that treatment of hyper-60 lungs with antimycin A
not only inhibited complex III-mediated DQH2 oxidation, but also
partially inhibited NQO1-mediated DQ reduction or other DQ
reductase(s).68 In addition to inhibiting DQH2 oxidation, antimycin A
would be expected to inhibit ATP production via oxidative
phosphorylation. This impairment to ATP production could stimulate
glycolysis1–3, 58 This, in turn, would divert glucose-6-phosphate from
the pentose phosphate pathway, the main source of NADPH for
NOQ1.13 This suggests that, for hyper-60 lungs, the rate of NAPDH
production in the presence of antimycin A may not be sufficient to
maintain the maximum capacity of NQO1 for DQ reduction that is
measurable in the absence of antimycin A (Figs. 2 and and4). This
explanation is consistent with previous studies that demonstrated that
rat exposure to hyper-85, but not hyper-60, increased lung activities
of glucose transporters, hexokinase, and glucose-6-phosphate
dehydrogenase (G-6-PHD) compared with normoxic lungs (Table 9).1–
3,40,64

Table 9. Summary of the effect of rat exposure to hyper-60 or hyper-85 for 7
days on cell surface, cytosolic, and mitochondrial enzymes
Hyper-60 for 7
days, %

Hyper-85 for 7
days, %

Reference
No.

+64

+40

Present study

Complex III per g dry wt

NS

+56

Present study

Complex I per mg protein

−51

−49

Present study

Complex IV per mg protein

NS

+90

Present study

ACE

NS

−57

Present study

+56

NS

Present study

NS

+20

Present
Study

NQO1 per g dry wt

kox per g dry wt
Lung glutathione content per g
dry wt
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Hyper-60 for 7
days, %

Hyper-85 for 7
days, %

Reference
No.

G-6-PDH per g dry wt

NS

+68

40

Hexokinase per mg protein

NA

+44

2

g-Glutamyltransferase per
μU/mg

NS

+220

67

G-6-PDH, glucose-6-phosphate dehydrogenase. NS, not significant; NA, not available.

Figure 7 shows high correlation between homogenate NQO1
activity and the capacity (Vmax1) of NQO1-mediated DQ reduction in
normoxic, hyper-60, and hyper-85 lungs. However, the increase in
Vmax1 is larger than the increase in NQO1 homogenate activity in
hyper-60 and hyper-85 lungs. One reason for this difference may be
that hyperoxia-induced changes in key aspects of the intact lung
environment that regulate NQO1 activity (e.g., availability of electron
donors and their accessibility to the enzyme) are not preserved in lung
homogenates.6 Another reason may be that other dicumarolinhibitable reductase(s) besides NQO1 contribute to DQ
reduction.37,68,72 Although NQO1 is predominantly a cytosolic enzyme
(>90%),55 noncytosolic NQO1 activity has been previously
reported.11,37,63 Thus another reason for the above difference may be
that these O2 levels induced an increase in NQO1 activity in the
noncytosolic fraction of the lung tissue, which was not preserved in the
tissue homogenate used for the NQO1 assay.

Fig. 7. Relationship between total NQO1 activity in lung tissue homogenates (Table 2)
and the capacity (Vmax1) of NQO1 mediated DQ reduction (Table 8) on passage
through the pulmonary circulation of normoxic, hyper-60, or hyper-85 lungs. Values
are means ± SE. Solid line is linear model fit (r2 = 0.975).
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Several studies have evaluated the role of NQO1 in protection
against pulmonary O2 toxicity.20,70 Whitney and Frank70 found that the
induction of NQO1 did not significantly improve the survivability of
adult rats exposed to lethal O2 levels. On the other hand, Cho et al.20
showed that mice deficient in the transcription factor Nrf2, which is
involved in the induction of phase II enzymes, including NQO1, had
significantly lower lung NQO1 mRNA expression and were significantly
more sensitive to hyperoxia (>95% O2 for 72 h) than wild-type mice.
Previously, our laboratory demonstrated that rat exposure to hyper-85
for 21 days, but not for 2 days, increased the capacity of NQO1mediated DQ reduction on passage through the lungs and suggested a
potential role for NQO1 in rat tolerance of 100% O2 toxicity.6,9 One of
the objectives of this study was to determine whether rat exposure to
hyper-60 or hyper-85 has a differential effect on the lung activity of
NQO1. The results of this study reveal that both hyperoxic O2 levels
increase NQO1 activity in the isolated perfused lung.
The difference in the rate of DQ efflux during DQH2 infusion in
the presence of dicumarol (Fig. 3) compared with that in the presence
of dicumarol plus rotenone (Fig. 5) is consistent with competition
between infused DQH2 and complex I-generated CoQ9H2 for complex
III-mediated oxidation. Hence, this difference is a measure of the
capacity of complex I for generating reducing equivalent (CoQ9H2) and
of lung tissue rotenone-sensitive O2 consumption. Previously, our
laboratory estimated the rate of rotenone-sensitive O2 consumption in
normoxic lungs to be ∼1.4 μmol·min−1·g dry lung wt−1.5 This rate
(which needs to be multiplied by two for comparison with the
difference in DQ efflux rate in Fig. 8) is comparable with the maximum
difference in DQ efflux rate (∼2.4 μmol·min−1·g dry lung wt−1) in
normoxic lungs (Fig. 8).
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Fig. 8. The relationship between the difference in steady-state rates (normalized to
dry lung weight) of DQ efflux and the log mean DQH2 concentrations during DQH2
arterial infusion in the presence of DIC plus ROT (Fig. 5) and DIC alone (Fig. 3), for
normoxic lungs, hyper-85 lungs, and hyper-60 lungs. Model-based interpolation was
used to determine the rates of DQ efflux in the presence of DIC plus ROT (Fig. 5) at
the same log mean DQH2 concentrations as in Fig. 3.

For hyper-85 lungs, the difference in the DQ efflux rate in the
presence of dicumarol or dicumarol plus rotenone (Fig. 8) was
comparable to that for normoxic lungs. However, for hyper-60 lungs,
the difference was ∼50% smaller than that for normoxic lungs (Fig. 8).
This suggests a potential decrease in the capacity of complex I for
generating CoQ9H2 in hyper-60 lungs compared with normoxic and
hyper-85 lungs. This could be due to a decrease in lung tissue complex
I activity and/or decrease in the rate of the metabolic coenzyme NADH
supplied to complex I. Table 3 shows that exposure to hyper-85 or
hyper-60 decreased lung complex I activity (per milligram of protein)
by ∼50%. This decrease appears to have no significant effect on the
capacity of complex I for generating CoQ9H2 in hyper-85 lungs (Fig. 8),
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suggesting a possible increase in the rate of NADH supplied to complex
I to compensate for the decrease in complex I activity. This would be
consistent with an increase in tissue activities of glucose transporters
and hexokinase in hyper-85 lungs.3 For hyper-60 lungs, the decrease
in complex I activity (Table 3) is proportional to the decrease in the
rate of complex I-generated CoQ9H2 (Fig. 8).
Ratner et al.53 demonstrated that exposure of neonatal mice to
hyperoxia (75% O2 for 72 h) decreases complex I activity by ∼70%,
and that this decrease compromises mitochondrial oxidative
phosphorylation and contributes to alveolar development arrest. Based
on these results, they concluded that the decrease in complex I plays
a key role in lung O2 toxicity. In the present study, exposure to hyper60 or hyper-85 decreased complex I activity by ∼50%. However, for
hyper-85 lungs, the effect of this decrease on oxidative
phosphorylation may have been countered by an increase in the lung
activities of glucose transporters and hexokinase upstream from
complex I,2 and by an increase in the activities of complexes III and IV
downstream from complex I (Table 9). Additional studies would be
needed to evaluate the effect of this depression in complex I activity
on the mitochondrial rate of ATP production.
Rat exposure to hyper-85, but not hyper-60, increased lung
tissue activities of complexes III and IV by 56 and 90%, respectively.
Again, this may be a compensatory mechanism to counter the
potential effects of the depression in complex I activity on
mitochondrial ATP production.28 The increase in lung complexes III and
IV activities could also be a means of decreasing ROS production at
complexes I and III, since the higher the respiration rate, the less time
the electrons are delayed at critical leakage sites, such as complexes I
and III.18,45 Campian et al.18 showed that an O2-tolerant strain of HeLa
cells had a higher complex IV activity and a lower rate of mitochondrial
ROS production compared with wild-type HeLa cells. Furthermore, they
showed that inhibiting the complex IV activity of these O2-tolerant cells
increased their rate of mitochondrial ROS production and increased
their sensitivity to hyperoxia. Based on these results, they attributed
the O2 tolerance of these cells to their higher than normal complex IV
activity, which results in a tighter coupling of the electron transport
chain and a lower rate of mitochondrial ROS formation.18 Additional
studies would be needed to evaluate the effect of the measured
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increase in tissue complexes III and IV activities of hyper-85 lungs on
mitochondrial rates of ATP production and ROS formation and to
determine the role of complexes III and IV in rat tolerance of 100% O2
toxicity.
Previous studies have suggested a role for the pentose
phosphate pathway in rat tolerance of 100% O2.64 This pathway
provides reducing equivalents (NADPH) for the glutathione redox cycle
and for the synthesis of cellular components needed for repair
mechanisms.64 Tierney et al.64 demonstrated an increase in the activity
of the enzyme G-6-PHD in lungs of rats, but not mice, exposed to
hyper-85. Hayatdavoudi et al.40 demonstrated an increase in G-6-PHD
activity in lungs of hyper-85 rats, but not hyper-60 rats. The results of
the present study demonstrate an increase in lung tissue total
glutathione (GSH) content per milligram of protein in hyper-85 lungs,
but not hyper-60 lungs, compared with normoxic lungs (Table 4). This
result is consistent with an increase in γ-glutamyltransferase activity in
tissue homogenates of hyper-85 lungs, but not hyper-60 lungs,
reported by Van Klaveren et al.67 (Table 9). This enzyme is important
for the uptake of substrates for intracellular GSH synthesis. However,
in the same study, Van Klaveren et al. reported no increase in GSH
level in hyper-85 tissue homogenates per milligram protein, which is
different from the results in the present study.67 This difference may
be due to differences in rat strains (Wistar vs. Sprague-Dawley)
and/or the methods used to measure tissue GSH content. The increase
in GSH content in hyper-85 lung homogenates measured in the
present study is potentially important, since GSH is the major
mechanism for scavenging H2O2 in endothelial cells, and since H2O2 is
the most cytotoxic ROS in endothelial cells, which are a primary target
of lung O2 toxicity.62
For hyper-60 lungs, the decrease in complex I activity did not
stimulate changes in substrate availability, activities of complexes III
and IV, GSH content, and/or G-6-PDH activity to counter the potential
effect of a 50% depression in complex I activity on mitochondrial rates
of ATP production and ROS formation, and on GSH redox cycle. This
could make hyper-60 lung cells susceptible to further injury by a
hyperoxia-induced increase in the rate of ROS formation. The increase
in the susceptibility of hyper-60 rats to 100% O2 toxicity could also be
due to changes in other cellular processes. For instance, hyper-60
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rates are more susceptible to mechanical ventilation injury than are
normoxic rats.40 Additional studies would be needed to evaluate the
effect of rat exposure to hyper-60 on lung tissue rates of mitochondrial
ROS formation and ATP production.
Since mice do not acquire tolerance of 100% O2 following
exposure to hyper-85,19,26 a lack of increase in complexes III and IV
activities and GSH content in lungs of mice exposed to hyper-85 would
provide further evidence for the potential role of these redox processes
in rat tolerance of 100% O2. However, the inability of mice to acquire
tolerance of 100% O2 could also be due to changes in other cellular
processes.
Rat tolerance of 100% O2 can be induced, not only by
preexposing rats to hyper-85 for 7 days, but also by other
experimental means, including rat preexposure to 95% O2 for 48 h,
followed by a 24-h “rest period” in room air or 50–70% O2 (hyper95).33 Thus another approach to providing additional support for the
potential role of complexes III and IV and GSH redox cycle in rat
tolerance of 100% O2 would be to demonstrate that their activities also
increase in lungs of rats exposed to hyper-95.
Because patients requiring high O2 come with differing
tolerances of hyperoxia based on genetics, preconditioning, or other
factors, real-time information that permits clinicians to determine
which patients are developing toxicity is invaluable.36 The identified
changes in complexes III and IV and GSH content may provide targets
for clinical biomarker imaging (e.g., SPECT, PET, MRI) to detect
tolerance of, or susceptibility to, high O2. For instance, the ability of
lung tissue to increase its capacity to generate GSH or increase its
activities of complexes III and IV may be indicative of the ability of a
critically ill patient to tolerate sustained exposure to O2 at high
fractions. In contrast, a patient with the same O2 requirement and no
increase in GSH content or activities of complexes III and IV could be
at a much higher risk for irreversible lung injury. In this case, the
patient with evidence of enhanced susceptibility to hyperoxia should be
a candidate for therapies that otherwise would not be employed
because of toxicity, e.g., higher positive end-expiratory pressure,
acceptance of lower arterial O2 tension, extracorporeal membrane
oxygenation, and moderate hypothermia.
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In conclusion, the results demonstrate that NQO1 activity
increased in both hyper-60 and hyper-85 lungs, whereas complex III
activity increased in hyper-85 lungs only. This increase, along with the
increase in complex IV activity, substrate availability, and G-6-PHD in
hyper-85 lungs, could be to counter the effects that the depression in
complex I activity might have on mitochondrial ATP production and
ROS formation, and on GSH redox cycle, and hence be important to
rat tolerance of 100% O2. The results demonstrate the utility of these
two hyperoxic models and indicator dilution methods for furthering
understanding of the pathogenesis of lung O2 toxicity and for providing
insights into the underlying mechanisms of rat tolerance of and
susceptibility to 100% O2.
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Glossary
ACE
Angiotensin-converting enzyme
BSA
Bovine serum albumin
CoQ9H2
Endogenous coenzyme Q9 hydroquinone
DQH2
Durohydroquinone
[DQ](x,t) and [DQH2](x,t)
Vascular concentrations of free DQ and DQH2, respectively, at distance
x from the capillary inlet and time t (μM)
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[DQ]
Total (free + BSA bound) vascular concentration of DQ (μM)
[DQH2]
Total (free + BSA bound) vascular concentration of DQH2 (μM)
hc(t)
Capillary transit time distribution
FAPGG
N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly
Km1a
Apparent Michaelis-Menten constant for NQO1-mediated DQ reduction
(μM)
Km2a
Apparent Michaelis-Menten constant for DQH2 oxidation via complex
III (μM)
kox
Tissue-mediated DQH2 oxidation rate on passage through the
pulmonary circulation in the absence of rotenone (ml/min)
NQO1
NAD(P)H:quinone oxidoreductase 1
PS
Permeability-surface area product (ml/min), which is a measure of rate
of ACE-mediated FAPGG hydrolysis, and an index of perfused capillary
surface area
Vc
Volume of the vascular region of the single capillary element model
(ml)
Ve
Volume of the tissue region of the single capillary element model (ml)
Vmax1
Maximum rate for DQ reduction via NQO1 (μmol/min)
Vmax2
Maximum rate for DQH2 oxidation via complex III (μmol/min)
VF1/α1
Virtual volume of distribution for DQ (ml)
VF2/α2
Virtual volume of distribution for DQH2 (ml)
W
Convective transport velocity (cm/min)
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Greek Letters
α1 and α2
Constants that
and DQH2 with
α3 and α4
Constants that
and DQH2 with

account for the rapidly equilibrating interactions of DQ
the 5% BSA (i.e., Pc) perfusate
account for the rapidly equilibrating interactions of DQ
lung tissue sites of association, respectively

Appendix
Based on the single capillary element model depicted in Fig. 6, the species
balance equations descriptive of spatial and temporal variations in the
concentrations of DQ, DQH2 in (Vc and Ve) are
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where W = convective transport velocity = L/t̄ c; x = 0 and x = L are
the capillary inlet and outlet, respectively; t̄ c is the capillary mean
transit time; [DQ](x,t), and [DQH2](x,t) are vascular concentrations of
free DQ and DQH2 forms, respectively, at distance x from the capillary
inlet and time t; [DQ] = α1 [DQ] and [DQH2] = α2 [DQH2] are the total
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(free + BSA bound) vascular concentrations of DQ and DQH2,
respectively; α1 = 1 + (DQ bound fraction/DQ free fraction) = 25 and
α2 = 1 + (DQH2 bound fraction/DQH2 free fraction) = 4.2 are constants
that account for the rapidly equilibrating interactions of DQ and DQH2,
with the 5% BSA (i.e., Pc) perfusate calculated from the fractions of
DQ and DQH2 bound to BSA obtained by ultrafiltration (5). Vmax1
(μmol/min) and Vmax2 (μmol/min) are the respective maximum rates
for DQ reduction via NQO1 and DQH2 oxidation via complex III; Km1a
(μM) and Km2a (μM) are the apparent Michaelis-Menten constants for
NQO1 and complex III, respectively. VF1/α1 = (α3/α1) Ve and VF2/α2 =
(α4/α2) Ve (ml) are the respective virtual volumes of distribution for DQ
and DQH2, where α3 and α4 are constants that account for the rapidly
equilibrating interactions of DQ and DQH2 with lung tissue sites (Pe) of
association, respectively.
In the absence of rotenone, DQH2 competes with CoQ9H2 for
oxidation via complex III. This competition explains the observation
that the rates of DQ efflux during DQH2 infusion in the presence of
dicumarol alone are lower than those in the presence of dicumarol plus
rotenone (Figs. 3 and and5).5). Moreover, the steady-state DQ efflux
rates during DQH2 infusion in the presence of dicumarol alone appear
to follow linear kinetics for the range of infused DQH2 concentrations
studied (Fig. 3). Thus, in the absence of rotenone, Vmax2 and Km2a in
Eqs. A1 and A2 are substituted for with a tissue-mediated DQH2
oxidation rate kox (ml/min). Equations A1 and A2 become
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Since our venous effluent data are measured at steady state, we
considered the steady-state version of Eqs. A1 and A2 and Eqs. A3 and
A4 obtained by setting all time derivative terms to zero. Thus Eqs. A1
and A2 and Eqs. A3 and A4 become Eqs. A5 and A6 and Eqs. A7 and
A8, respectively. Under steady-state conditions, the unknown model
parameters are Vmax1, Vmax2, Km1a, Km2a, and kox.
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Equations A1 and A2 or Eqs. A3 and A4 are for a single capillary
element. For the lung model, we accounted for the effect of the hc(t)
on the plasma concentrations and redox status of DQ and DQH2 on
passage through the pulmonary circulation (5, 6). Previously, our
laboratory determined hc(t) for normoxic rat lungs and hyper-85 lungs
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and demonstrated that rat exposure to hyper-85 for 7 days decreased
capillary mean transit time by 42% and increased the relative
dispersion of hc(t) by 40% (52). These values were used in the kinetic
analysis of the normoxic and hyper-85 lung data. For hyper-60 lungs,
hc(t) was assumed to be the same as that determined for normoxic
lungs. This is based on results in Table 1 that show exposure to hyper60 for 7 days had no effect on perfused capillary surface area (PS) and
on previous results that showed rat exposure to hyper-60 for 7 days
had no significant effect on morphometrically measured lung capillary
endothelial surface area and capillary volume (40).
Previously, our laboratory demonstrated that most of the
dispersion within the lung vascular region is due to the capillary bed
(52). Thus DQ and DQH2 transit through the arteries and veins was
represented by a shifted impulse function, where the shift is the
plasma mean transit time through the arteries and veins, determined
as previously described (52).
To model DQ or DQH2 pulse infusions, given hc(t), Eqs. A1 and
A2 or Eqs. A3 and A4 are solved numerically with appropriate initial (t
= 0) and boundary (x = 0) conditions (5, 7, 8). To provide the whole
organ output [DQ] and [DQH2], the outputs for all transit times are
summed, each weighted according to hc(t), as previously described (5,
7, 8).
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